Who are ARS Pharmaceuticals, Inc.'s main suppliers?

ARS Pharmaceuticals, Inc. (SPRY) key suppliers include: Alaska Air Group, Inc., Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc., Aquestive Therapeutics, Inc., AptarGroup, Inc. and 3 more. View the full supplier network at chainsifter.com/chain/SPRY.

Who are ARS Pharmaceuticals, Inc.'s major customers?

ARS Pharmaceuticals, Inc. (SPRY) key customers include: CUSTOMER, ALFRESA, ALK-U-S, PEDIATRIX-THERAPEUTICS, Amneal Pharmaceuticals, Inc. and 16 more. View the full customer network at chainsifter.com/chain/SPRY.

What sector is ARS Pharmaceuticals, Inc. in?

ARS Pharmaceuticals, Inc. (SPRY) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

ARS Pharmaceuticals, Inc. Suppliers, Customers & Supply Chain (SPRY)

8Suppliers

21Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

ARS Pharmaceuticals, Inc. (SPRY) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

33Total relationships

4Distinct source URLs

9High confidence

0.740Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

ARS Pharmaceuticals, Inc. Suppliers

Ticker	Name	Confidence	Evidence
ALK	Alaska Air Group, Inc.	92%	Reciprocal relationship from ALK graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from ALK graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from ALK grap…
AMRX	Amneal Pharmaceuticals, Inc.	72%	. We believe that NARCAN’s widespread use clearly demonstrates market uptake in response to the advantages of an intranasal product via proven device over injection, considering in particular that NA…
AMRX	Amneal Pharmaceuticals, Inc.	72%	Reciprocal relationship from AMRX graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from AMRX g…
AQST	Aquestive Therapeutics, Inc.	72%	Reciprocal relationship from AQST graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from AQST graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from AQST g…
ATR	AptarGroup, Inc.	72%	Reciprocal relationship from ATR graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from ATR graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from ATR grap…
NSRX	Nasus Pharma Ltd.	72%	Reciprocal relationship from NSRX graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from NSRX graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from NSRX g…
ORANY	ORANY	72%	tory concern. We may terminate the ALK Agreement in the event ALK makes certain challenges to certain of our patents. Prior to a change of control and outside of a set period of time after which we c…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from ORAN…

ARS Pharmaceuticals, Inc. Customers

Ticker	Name	Confidence	Evidence
CUSTOMER	CUSTOMER	92%	For the three months ended March 31, 2026 , three customers accounted for 99 % of revenue under supply agreements
ALFRESA	ALFRESA	90%	we will supply Alfresa's requirements (and Alfresa will purchase from ARS its requirements) for a transfer price in the low-double-digit percentage on net sales of neffy in Japan
ALK-U-S	ALK-U-S	90%	we granted ALK U.S. a non-exclusive, royalty-free license to use the neffy trademarks and copyrights and the ARS house marks in the U.S. solely in connection with promoting neffy
PEDIATRIX-THERAPEUTICS	PEDIATRIX-THERAPEUTICS	80%	In March 2021, we entered into a collaboration and distribution agreement (the “Pediatrix Agreement”) with Pediatrix Therapeutics (“Pediatrix”).
AMRX	Amneal Pharmaceuticals, Inc.	72%	. We believe that NARCAN’s widespread use clearly demonstrates market uptake in response to the advantages of an intranasal product via proven device over injection, considering in particular that NA…
AMRX	Amneal Pharmaceuticals, Inc.	72%	Reciprocal relationship from AMRX graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from AMRX graph: Reciprocal relationship from SPRY graph: . We believe that NARCAN’s widespre…
AQST	Aquestive Therapeutics, Inc.	72%	Reciprocal relationship from AQST graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from AQST graph: Reciprocal relationship from SPRY graph: Reciprocal relationship from AQST g…
AQST	Aquestive Therapeutics, Inc.	72%	higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Nasus Pharma Ltd., Orexo AB, Insignis Therapeutics, Inc. and Belhaven BioPharma.…
NSRX	Nasus Pharma Ltd.	72%	Reciprocal relationship from NSRX graph: Reciprocal relationship from SPRY graph: higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.)…
NSRX	Nasus Pharma Ltd.	72%	higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Nasus Pharma Ltd., Orexo AB, Insignis Therapeutics, Inc. and Belhaven BioPharma.…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from SPRY graph: tory concern. We may terminate the ALK Agreement in the event ALK makes certain challenges to certain of our patents…
ORANY	ORANY	72%	tory concern. We may terminate the ALK Agreement in the event ALK makes certain challenges to certain of our patents. Prior to a change of control and outside of a set period of time after which we c…
AEGIS-THERAPEUTICS-LLC	AEGIS-THERAPEUTICS-LLC	62%	onths. Epinephrine injectable products have a reported shelf-life range from the date of product manufacture of 18 to 24 months, with a volume-weighted average shelf-life of approximately 22 to 23 mo…
ALFRESA-PHARMA-CORPORATION	ALFRESA-PHARMA-CORPORATION	62%	y products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive product lines; and • unforeseen delays, costs and expenses a…
BELHAVEN-BIOPHARMA-AQUESTIVE-THERAPEUTICS-INC	BELHAVEN-BIOPHARMA-AQUESTIVE-THERAPEUTICS-INC	62%	higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Nasus Pharma Ltd., Orexo AB, Insignis Therapeutics, Inc. and Belhaven BioPharma.…
BRYN-PHARMA-HIKMA-PHARMACEUTICALS-INC	BRYN-PHARMA-HIKMA-PHARMACEUTICALS-INC	62%	higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Nasus Pharma Ltd., Orexo AB, Insignis Therapeutics, Inc. and Belhaven BioPharma.…
COORDINATION-GROUP	COORDINATION-GROUP	62%	ivacy and security of personal information, including health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in sign…
OREXO-AB-INSIGNIS-THERAPEUTICS-INC	OREXO-AB-INSIGNIS-THERAPEUTICS-INC	62%	higher dose spray candidates including Bryn Pharma, Hikma Pharmaceuticals, Inc. (previously INSYS Therapeutics, Inc.), Nasus Pharma Ltd., Orexo AB, Insignis Therapeutics, Inc. and Belhaven BioPharma.…
PEDIATRIX-THERAPEUTICS-INC	PEDIATRIX-THERAPEUTICS-INC	62%	y products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies that have more extensive product lines; and • unforeseen delays, costs and expenses a…
RECORDATI-IRELAND-LTD	RECORDATI-IRELAND-LTD	62%	9.0 million as of December 31, 2025. We are also required to make royalty payments to OrbiMed based on a mid-single-digit percentage of net product sales. Future royalty payment amounts are indetermi…
SEQIRUS-PTY-LTD	SEQIRUS-PTY-LTD	62%	onal clinical studies required for approval of neffy in Japan. The Alfresa Agreement will continue until the later of (i) expiration of the last-to-expire valid claim of our patents or joint patent w…

ARS Pharmaceuticals, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
SPRY-DEBT	Debt stack $96.7M	90%	Market cache reports total debt of $96.7M.
SPRY-DEBT-12715	Warrants outstanding: 223000	90%	xbrl warrant detail from xbrl 2023-12-31.
SPRY-DEBT-12716	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2022-12-31.

ARS Pharmaceuticals, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for ARS Pharmaceuticals, Inc..

ARS Pharmaceuticals, Inc. Ownership

Holder	Name	Confidence	Evidence
SPRY-OWNER-RA-CAPITAL-MANAGEMENT-L-P	RA CAPITAL MANAGEMENT, L.P.	90%	13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 204 tracked holders.

ARS Pharmaceuticals, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
ASRT	Assertio Holdings, Inc.	100.00	2
ALK	Alaska Air Group, Inc.	100.00	1	['supplier']
AQST	Aquestive Therapeutics, Inc.	100.00	1	['customer', 'supplier']
NSRX	Nasus Pharma Ltd.	100.00	1	['customer', 'supplier']
AMRX	Amneal Pharmaceuticals, Inc.	100.00	1	['customer', 'supplier']
AMZN	Amazon.com, Inc.	100.00	2
ATR	AptarGroup, Inc.	100.00	1	['supplier']
SKYW	SkyWest, Inc.	100.00	2
VLRS	Controladora Vuela Compañía de Aviación, S.A.B. de C.V.	100.00	2
AMAZON	AMAZON	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
ASBPW	Aspire Biopharma Holdings, Inc.	50.00	2
ALKS	Alkermes plc	50.00	2
ARQQW	Arqit Quantum Inc.	50.00	2
CPRX	Catalyst Pharmaceuticals, Inc.	50.00	2
BLTE	Belite Bio, Inc	50.00	2
BCDRF	Banco Santander, S.A.	50.00	2
AMZE	Amaze Holdings, Inc.	50.00	2
D	Dominion Energy, Inc.	50.00	2
BFRIW	Biofrontera Inc.	50.00	2

ARS Pharmaceuticals, Inc. Supply Chain